# A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

> **NCT03711188** · PHASE2 · COMPLETED · sponsor: **Immodulon Therapeutics Ltd** · enrollment: 16 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** IMM-101

## Key facts

- **NCT ID:** NCT03711188
- **Lead sponsor:** Immodulon Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-04
- **Primary completion:** 2021-12-02
- **Final completion:** 2021-12-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03711188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03711188, "A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT03711188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*